Hologic, Inc.

| Biotech | Medical technology, women's health

General analysis — not personal advice.

Signal

NEUTRAL

Sentiment

6/10

Risk

7/10

Post-take-private there is no public equity to trade; for former shareholders the remaining value driver is the CVR and its revenue conditions.

This picture changes. Follow Hologic, Inc. free — email when the signal or risk changes + a Sunday weekly brief.

Follow Hologic, Inc. free

Email when the signal or risk changes · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Market sentiment

Social sentiment is mostly neutral to slightly positive: attention centers on the cash payout, uncertainty around the CVR earn-out, and reduced transparency post-delisting.

Why NEUTRAL?

Post-take-private there is no public equity to trade; for former shareholders the remaining value driver is the CVR and its revenue conditions. The appropriate stance is therefore NEUTRAL (monitor) rather than buy/sell, focusing on the likelihood of Breast Health meeting FY2026–FY2027 targets.

Monitor/evaluate CVR exposure (if applicable) and track any updates on Breast Health revenue performance; no public share position can be initiated after delisting.

We're already tracking Hologic, Inc. — here are the latest events we've registered

Recent News

On April 7, 2026, Blackstone and TPG completed the acquisition of Hologic and the shares were delisted from Nasdaq. Shareholders received $76 per share in cash plus a non-transferable CVR worth up to $3 depending on Breast Health revenue targets in FY2026–FY2027. Joe E. Almeida became CEO; as a private company, disclosure is expected to be reduced, and OCC adjusted listed options to cash settlement.

Dilution Risk

Assessment: Low

Create free account — follow 3 companies

What Firelda Watch includes for Hologic, Inc.

Add the company to your watchlist and get all of this automatically.

Free: 3 companies on your watchlist
Change history and monitoring for every company you follow
Sunday weekly brief — AI roundup of the week's news
Watch/Ultra: same-day email when something material happens

Want to see what a finished analysis looks like?

View a sample analysis

This is a real Firelda analysis. Your analysis of Hologic, Inc. will be delivered in the same format.

Own Hologic, Inc.? Create a free account and follow up to 3 companies — change history, weekly brief, and email when the picture changes. Upgrade to Watch for more slots and same-day alerts.

Follow 3 companies free